Pravastatin inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages 5331-5340

  Haydont, Valérie ^a,b   Bourgier, Céline ^a,b   Pocard, Marc ^a,c   Lusinchi, Antoine ^a   Aigueperse, Jocelyne ^b   Mathé, Denis ^a   Bourhis, Jean ^a   Vozenin Brotons, Marie Catherine ^a,b,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d Laboratoire UPRES EA 27 10   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CCN2 PROTEIN; COLLAGEN TYPE 1; DRINKING WATER; FIBRONECTIN; GROWTH FACTOR; PRAVASTATIN; RHO FACTOR; ROCK PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; EXPLANT; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; INTESTINAL FIBROSIS; MALE; MESENCHYME CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUALITY OF LIFE; RADIATION; RADIATION ENTEROPATHY; RADIATION EXPOSURE; RAT; SMOOTH MUSCLE FIBER;

ANIMALS; EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTESTINAL DISEASES; INTESTINES; MALE; PRAVASTATIN; RADIATION INJURIES; RATS; RATS, WISTAR; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES;

EID: 34848906040     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0625     Document Type: Article

References (43)

1. Toledano A, Garaud P, Serin D, et al. Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study. Int J Radiat Oncol Biol Phys 2006;65:324-32.
2. Andreyev J. Gastrointestinal complications of pelvic radiotherapy: are they of any importance? Gut 2005;54:1051-4.
3. Hauer-Jensen M, Wang J, Denham JW. Bowel injury: current and evolving management strategies. Semin Radiat Oncol 2003;13:357-71.
4. Graham MF. Pathogenesis of intestinal strictures in Crohn's disease - an update. Inflamm Bowel Dis 1995;1:220-7.
5. Delanian S, Lefaix JL. The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol 2004;73:119-31.
6. Delanian S, Porcher R, Rudant J, Lefaix JL. Kinetics of response tolong-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol 2005;23:8570-9.
7. Gothard L, Cornes P, Earl J, et al. Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. Radiother Oncol 2004;73:133-9.
8. Anscher MS. The irreversibility of radiation-induced fibrosis: fact or folklore? J Clin Oncol 2005;23:8551-2.
9. Hovdenak N, Wang J, Sung CC, Kelly T, Fajardo LF, Hauer-Jensen M. Clinical significance of increased gelatinolytic activity in the rectalmucosa during external beam radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:919-27.
10. Strup-Perrot C, Mathe D, Linard C, et al. Global gene expression profiles reveal an increase in mRNA levels of collagens, MMPs, and TIMPs in late radiation enteritis. Am J Physiol Gastrointest Liver Physiol 2004;287:G875-85.
11. Vozenin-Brotons MC, Milliat F, Sabourin JC, et al. Fibrogenic signals in patients with radiation enteritis are associated with increased connective tissue growth factor expression. Int J Radiat Oncol Biol Phys 2003;56:561-72.
12. Bourgier C, Haydont V, Milliat F, et al. Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. Gut 2005;54:336-43.
13. Haydont V, Bourgier C, Vozenin-Brotons MC. Rho/ROCK pathway as molecular target for modulation of intestinal radiation-induced toxicity. Br J Radiol 2007;80:532-40.
14. Vozenin-Brotons MC, Milliat F, Linard C, et al. Gene expression profile in human late radiation enteritis obtained by high-density cDNA array hybridization. Radiat Res 2004;161:299-311.
15. Haydont V, Mathe D, Bourgier C, et al. Induction of CTGF by TGF-β1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives. Radiother Oncol 2005;76:219-25.
16. Dubreuil CI, Winton MJ, McKerracher L. Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J Cell Biol 2003;162:233-43.
17. Augustine AD, Gondre-Lewis T, McBride W, Miller L, Pellmar TC, Rockwell S. Animal models for radiation injury, protection and therapy. Radiat Res 2005;164:100-9.
18. Barcellos-Hoff MH, Costes SV. A systems biology approach to multicellular and multi-generational radiation responses. Mutat Res 2006;597:32-8.
19. Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990;1045:115-20.
20. Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer Epidemiol Biomarkers Prev 2005;14:1897-8.
21. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-70.
22. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 2003;4:446-56.
23. Rolfe BE, Worth NF, World CJ, Campbell JH, Campbell GR. Rho and vascular disease. Atherosclerosis 2005;183:1-16.
24. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci 2002;23:482-6.
25. Shi J, Wang J, Zheng H, et al. Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor α-induced thrombomodulin downregulation. Blood Coagul Fibrinolysis 2003;14:575-85.
26. Gaugler MH, Vereycken-Holler V, Squiban C, Vandamme M, Vozenin-Brotons MC, Benderitter M. Pravastatin limits endothelial activation after irradiation and decreases the resulting inflammatory and thrombotic responses. Radiat Res 2005;163:479-87.
27. Shiga N, Hirano K, Hirano M, Nishimura J, Nawata H, Kanaide H. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ Res 2005;96:1014-21.
28. Veillard NR, Braunersreuther V, Arnaud C, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006;188:51-8.
29. Denham JW, Hauer-Jensen M. The radiotherapeutic injury - a complex 'wound'. Radiother Oncol 2002;63:129-45.
30. Fajardo LG. Pathology of radiation injury. In: SS Sterberg, editor. Masson Monographs in Diagnostic Pathology. Chicago (IL). Year Book Medical Publishers; 1982. p. 47-76.
31. Williams JP, Hernady E, Johnston CJ, et al. Effect of administration of lovastatin on the development of late pulmonary effects after whole-lung irradiation in a murine model. Radiat Res 2004;161:560-7.
32. Zheng H, Wang J, Hauer-Jensen M. Role of mast cells in early and delayed radiation injury in rat intestine. Radiat Res 2000;153:533-9.
33. Martin M, Lefaix J, Delanian S. TGF-β1 and radiation fibrosis: a master switch and a specific therapeutic target? Int J Radiat Oncol Biol Phys 2000;47:277-90.
34. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 2002;21:473-82.
35. Heusinger-Ribeiro J, Fischer B, Goppelt-Struebe M. Differential effects of simvastatin on mesangial cells. Kidney Int 2004;66:187-95.
36. Eberlein M, Heusinger-Ribeiro J, Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001;133:1172-80.
37. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006;10:76-99.
38. Vozenin-Brotons MC, Sivan V, Gault N, et al. Antifibrotic action of Cu/Zn SOD is mediated by TGF-β1 repression and phenotypic reversion of myofibroblasts. Free Radic Biol Med 2001;30:30-42.
39. Bayreuther K, Rodemann HP, Hommel R, Dittmann K, Albiez M, Francz PI. Human skin fibroblasts in vitro differentiate along a terminal cell lineage. Proc Natl Acad Sci U S A 1988;85:5112-6.
40. Rodemann HP, Bamberg M. Cellular basis of radiation-induced fibrosis. Radiother Oncol 1995;35:83-90.
41. Stratton R, Rajkumar V, Ponticos M, et al. Prostacyclin derivatives prevent the fibrotic response to TGF-β by inhibiting the Ras/MEK/ERK pathway. FASEB J 2002;16:1949-51.
42. Liu Y. Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol Renal Physiol 2004;287:F7-16.
43. Haydont V, Gilliot O, Rivera S, et al. Successful mitigation of delayed intestinal radiation injury using pravastatin is not associated with acute injury improvement nor tumor protection. Int J Radiat Oncol Biol Phys 2007;68:1471-82.